- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03763474
Euglyca Application in Children and Adolescents With Type 1 Diabetes Mellitus
The Effect of Mobile Application Euglyca in Glycemic Control of Children and Adolescents With Diabetes Mellitus Type-1
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Children and adolescents with Diabetes Mellitus Type 1 (T1DM) who visited consecutively this clinic were asked to participate in the study if they owned an Android smartphone and were familiar with its use. Patients were included after one of their parents or their legal guardian signed an informed consent. Inclusion criteria were: 1. Treatment with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII); 2. satisfactory knowledge of the concept of carbohydrates and lipids counting acquired following previous training by the physicians and nutritionist of the department at initial diagnosis and thereafter during follow-up visits. Exclusion criteria were: 1. Use of another medical application for diabetes in the previous 3 months; 2. lack of capacity of reading greek.
80 patients met the inclusion criteria and agreed to participate in the study. Subsequently they were randomized to two equally numbered groups by drawing one of two nontransparent envelopes which contained one ticket inscribed with either a E (for Euglyca group) or a C (for Control group). To ensure equal allocation rates within the 2 groups, block randomization was employed.
At the initial visit, patients randomized to the E group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose they were injected. Patients randomized to the C group were advised to calculate bolus insulin dose they were injected, the way they used to do. Patients repeated their visit to the endocrine pediatric clinic at 3, 6 and 12 months, the latter set as the terminal time-point of this study following the initial visit. At all 4 visits, anthropometrics (weight, height, BMI), blood pressure measurement and heart rate were noted down, while a peripheral blood sample was drawn from all patients in the morning of each visit after an overnight fast for measurement of glycemia and glycosylated hemoglobin (HbA1c) levels. Glucose measurements between 70 and 180 mg/dl were categorized as normoglycemia; any glucose measurement below 70mg/dl was categorized as hypoglycemia; glucose measurements at two hours postprandial measurement found above 180mg/dl were categorized as hyperglycemia. At baseline (first visit), at 6 months (third visit) and at terminal time-point (12 months) all patients filled the World Health Organization-Standard DTSQ. Patients' logbooks and readings from their glucose meters were reviewed by the physicians and nutritionist of the department at each of the four visits and the percentage of normoglycemic, hypoglycemic and hyperglycemic episodes during the preceding trimester was calculated for each patient. The change of HbA1c values from baseline to the terminal time-point for each group was set as primary outcome, while the percentage of normoglycemic, hypoglycemic and hyperglycemic events over the total number of glucose measurements during the preceding trimester of each visit was set as secondary outcome.
Glycosylated hemoglobin was determined by Siemens DCA Vantage point-of-care immunoassay analyzer (Siemens Health care Diagnostics Ltd., Frimley, Camberley, UK) with intra- and inter- assay coefficients of variation (CV) 5% and 8%, respectively; glycemia was determined by glucose god/pap kit with intra- and inter- assay CVs 5.7% and 7.8%, respectively.
'Euglyca' is a mobile application that we developed . The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
Sample size was determined by estimating the change in HbA1c values (primary outcome) based on previous studies (7, 8), assuming 0.5% reduction in HbA1c in the intervention group with 80% power and 5% significance level. Power calculation resulted in 14 patients per group, while the target of the study had been set at recruitment of 80 patients altogether. Results are reported as mean ± standard deviation (SD) for quantitative variables. The absolute difference in a quantitative variable between two different time points was defined as Δ. All quantitative variables (HbA1c; ΔHbA1c; percentages of normoglycemic, hypoglycemic and hyperglycemic events over a total number of glucose measurements; DTSQ's scores) were normally distributed and they were compared between the two studied groups of patients at the different time-points by employing General Linear Models ANOVA and Bonferroni post-hoc test. Repeated measures ANOVA involved one factor between patients (factor "Group" with two levels) and one factor for the repeated measures within patients (factor "time" with 4 or 3 levels depending on the compared variable). Qualitative variables (gender and type of therapy) were compared by employing x2 (chi square) test after having computed absolute and relative frequencies (percentages %), Statistical significance was set at P<0,05. An intention to treat analysis was followed. IBM SPSS V23 Chicago, USA software was used for the statistical analysis.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Thessaloniki, Grækenland, 54642
- Endocrine Unit of 3rd Department of Pediatrics of Aristotle University of Thessaloniki, Hippokration General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Children and adolescents with Diabetes Mellitus type 1.
- Treatment with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
- Satisfactory knowledge of the concept of carbohydrates and lipids counting
Exclusion Criteria:
- Use of another medical application for diabetes in the previous 3 months;
- Lack of capacity of reading greek.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Ingen indgriben: Styring
|
|
Eksperimentel: Euglyca
Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
|
'Euglyca' is a mobile application developed by two of the authors (CC and DF).
The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them.
Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application.
By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Level of glycosylated hemoglobin in the 2 groups
Tidsramme: At 3 months after the baseline visit
|
Comparison of the level of glycosylated hemoglobin between the 2 groups
|
At 3 months after the baseline visit
|
Level of glycosylated hemoglobin in the 2 groups
Tidsramme: At 6 months after the baseline visit
|
Comparison of the level of glycosylated hemoglobin between the 2 groups
|
At 6 months after the baseline visit
|
Level of glycosylated hemoglobin in the 2 groups
Tidsramme: At 12 months after the baseline visit
|
Comparison of the level of glycosylated hemoglobin between the 2 groups
|
At 12 months after the baseline visit
|
Change from Baseline glycosylated hemoglobin at 3 months in the 2 groups
Tidsramme: At 3 months after the baseline visit
|
Comparison of the differences in the level of glycosylated hemoglobin between the 2 groups
|
At 3 months after the baseline visit
|
Change from 3 months glycosylated hemoglobin at 6 months in the 2 groups
Tidsramme: At 6 months after the baseline visit
|
Comparison of the differences in the level of glycosylated hemoglobin between the 2 groups
|
At 6 months after the baseline visit
|
Change from 6 months glycosylated hemoglobin at 12 months in the 2 groups
Tidsramme: At 12 months after the baseline visit
|
Comparison of the differences in the level of glycosylated hemoglobin between the 2 groups
|
At 12 months after the baseline visit
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Normoglycemias in the 2 groups
Tidsramme: At 3 months after the baseline visit
|
Comparison of the percentage of Normoglycemias between the 2 groups
|
At 3 months after the baseline visit
|
Percentage of Normoglycemias in the 2 groups
Tidsramme: At 6 months after the baseline visit
|
Comparison of the percentage of Normoglycemias between the 2 groups
|
At 6 months after the baseline visit
|
Percentage of Normoglycemias in the 2 groups
Tidsramme: At 12 months after the baseline visit
|
Comparison of the percentage of Normoglycemias between the 2 groups
|
At 12 months after the baseline visit
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups
Tidsramme: At 3 months after the baseline visit
|
Comparison of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) score between the 2 groups. DTSQ consists of 8 elements. Each element can be graded in a scale from 0 to 6. Two of the elements concern the perceived hypoglycemia or hyperglycemia. By adding the grades of each of the rest 6 elements the DTSQ score is calculated. |
At 3 months after the baseline visit
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups
Tidsramme: At 6 months after the baseline visit
|
Comparison of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) score between the 2 groups. DTSQ consists of 8 elements. Each element can be graded in a scale from 0 to 6. Two of the elements concern the perceived hypoglycemia or hyperglycemia. By adding the grades of each of the rest 6 elements the DTSQ score is calculated. |
At 6 months after the baseline visit
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score in the 2 groups
Tidsramme: At 12 months after the baseline visit
|
Comparison of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) score between the 2 groups. DTSQ consists of 8 elements. Each element can be graded in a scale from 0 to 6. Two of the elements concern the perceived hypoglycemia or hyperglycemia. By adding the grades of each of the rest 6 elements the DTSQ score is calculated. |
At 12 months after the baseline visit
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Euglyca application
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus, type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAfsluttetType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | IDDMForenede Stater, Australien
-
Capillary Biomedical, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, insulinafhængig, 1Australien
-
Spiden AGDCB Research AGRekrutteringType 1 diabetes mellitus | Type 1 diabetes mellitus med hypoglykæmi | Type 1 diabetes mellitus med hyperglykæmiSchweiz
-
Capillary Biomedical, Inc.AfsluttetType 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, type I | Diabetes mellitus, insulinafhængig, 1 | IDDMØstrig
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute...UkendtType 1 diabetes mellitus med hyperglykæmi | Type 1 diabetes mellitus med hypoglykæmiPolen
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AfsluttetType 1 diabetes mellitus | T1DM | T1D | Nyopstået type 1-diabetes mellitusForenede Stater, Australien
-
Shanghai Changzheng HospitalRekrutteringSkør type 1 diabetes mellitusKina
-
National Institute of Diabetes and Digestive and...AfsluttetDiabetes mellitus type 1Forenede Stater
-
Stem Cells ArabiaAfsluttetGlukosemetabolismeforstyrrelser | Metaboliske sygdomme | Sygdomme i immunsystemet | Autoimmune sygdomme | Sygdomme i det endokrine system | Diabetes mellitus type 1Jordan
Kliniske forsøg med Euglyca application
-
Johan Sanmartin BerglundAndaluz Health Service; Universidad Politecnica de Madrid; Anglia Ruskin... og andre samarbejdspartnereUkendtMild demens | Kognitiv svækkelse, mildBelgien, Tjekkiet, Spanien, Sverige
-
Medical University of South CarolinaAfsluttet
-
Gazi UniversityAfsluttetGravid kvinde | Mobilapplikationer | Tilpasning | Postpartum periodeKalkun
-
National Taiwan University HospitalRekruttering
-
Hospital Universitari de BellvitgeAfsluttetVægttab | Sygelig fedmeSpanien
-
Kocaeli UniversityAfsluttetPostoperative komplikationer | Sygeplejerskens rolle | Klinisk forringelseKalkun
-
Ann & Robert H Lurie Children's Hospital of ChicagoSilicon Valley Community FoundationUkendtKræft | BørnekræftForenede Stater
-
Dornier MedTech SystemsAfsluttetErektil dysfunktion | Seksuel dysfunktion, FysiologiskForenede Stater
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiAfsluttet
-
Emory UniversityGeorgia Institute of TechnologyAfsluttetSelvmord, selvmordstankerForenede Stater